PROJECTS & INITIATIVES
Value of Treatment (draft)
“Value of Treatment: Bridging the Early Diagnosis and Treatment Gap for Brain Disorders”
The Value of Treatment research project draws from the EBC Report “The Economic Cost of Brain Disorders in Europe” published in 2005 (Balak and Elmaci 2007) and updated in 2010 (Gustavsson et al. 2011) that provided a solid estimation on the economic costs of brain disorders in Europe. The indirect costs of brain disorders make up for 40 percent of the total costs – which EBC estimated at around 800 billion euros per year in Europe.
The Value of Treatment Research Project will ultimately provide evidence-based and cost-effective policy recommendations for the adoption and implementation of a more patient-centred and sustainable coordinated care model for brain disorders.
The Value of Treatment (VoT) project is supported through financial contributions from:
Biogen, BMS-Pfizer Alliance, Boehringer Ingelheim GmbH, Grunenthal, Janssen, Livanova, Lundbeck, Medtronic, MSD, Novartis, Pfizer, Roche, Takeda, TEVA Pharmaceuticals, UCB Biopharma, Vifor Pharma, EARLS and EURLSSG.